Vimarsana
Biggest News Aggregation in the World

Ipsen Cares News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ipsen Cares. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ipsen Cares Today - Breaking & Trending Today

Ipsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA   -February 13, 2024 at 04:09 pm EST - Vimarsana News

Ipsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA   -February 13, 2024 at 04:09 pm EST

Published: February 13, 2024

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and...

Source: marketscreener.com
Related Topics:
United StatesSan FranciscoT Ai PeiFrance GeneralZev WainbergJulie FleshmanChristelle HuguetIpsen EuronextRachel ReiffDrug AdministrationAmerican Cancer SocietyPancreatic Cancer Action Network PanHead Of ResearchNational Comprehensive Cancer NetworkUcla Gi Oncology ProgramIpsen Biopharmaceuticals IncPancreatic Cancer Action NetworkNational Comprehensive CancerIpsen CaresIpsen Fast TrackNorth AmericaSouth AmericaRare DiseaseSponsored Leveli American Depositary ReceiptLung Disease
Ipsen's Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA - Vimarsana News

Ipsen's Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

Published: February 13, 2024

13.02.2024 - Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and progression-free survival versus ...

Source: wallstreet-online.de
Related Topics:
United StatesSan FranciscoT Ai PeiRachel ReiffJulie FleshmanZev WainbergIpsen Biopharmaceuticals IncAmerican Cancer SocietyPancreatic Cancer Action Network PanUcla Gi Oncology ProgramNational Comprehensive Cancer NetworkDrug AdministrationPancreatic Cancer ActionNational Comprehensive CancerIpsen CaresIpsen Fast TrackNorth AmericaSouth AmericaRare DiseaseSponsored Leveli American Depositary ReceiptLung DiseaseHypersensitivity ReactionFetal ToxicityReproductive PotentialIpsen Biopharmaceuticals
Ipsen's Onivyde® regimen, a potential new standard-of-care - Vimarsana News

Ipsen's Onivyde® regimen, a potential new standard-of-care

Published: February 13, 2024

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically...

Source: globenewswire.com
Related Topics:
United StatesSan FranciscoT Ai PeiFrance GeneralZev WainbergJulie FleshmanChristelle HuguetIpsen EuronextRachel ReiffUcla Gi Oncology ProgramIpsen Biopharmaceuticals IncNational Comprehensive Cancer NetworkHead Of ResearchAmerican Cancer SocietyDrug AdministrationPancreatic Cancer Action Network PanPancreatic Cancer Action NetworkNational Comprehensive CancerIpsen CaresIpsen Fast TrackNorth AmericaSouth AmericaRare DiseaseSponsored Leveli American Depositary ReceiptLung Disease
US FDA approves Ipsen's SohonosTM (palovarotene) capsules, - Vimarsana News

US FDA approves Ipsen's SohonosTM (palovarotene) capsules,

Published: August 16, 2023

Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia...

Source: globenewswire.com
Related Topics:
France GeneralUnited Arab EmiratesSan FranciscoUnited StatesUnited KingdomEdward HsiaoAmy WolfHoward MayerRachel ReiffIpsen EuronextAnna GibbinsNicolas BoglerAl MukaddamMichelle DavisIoana PiscociuVal HealthEuropean CommissionUniversity Of CaliforniaGlobal Head Of Franchise CommunicationsInternational Fibrodysplasia Ossificans ProgressivaDrug AdministrationAssociation Global RegistryDivision Of EndocrinologyMineral ResearchUs Head Of Franchise Communications
US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva - Vimarsana News

US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

Published: August 16, 2023

Breakthrough treatment reduces new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, fibrodysplasia ossificans progressiva FOP impacts about 400... -Today at 03:33 pm- MarketScreener

Source: marketscreener.com
Related Topics:
France GeneralSan FranciscoUnited StatesUnited Arab EmiratesUnited KingdomHoward MayerAnna GibbinsNicolas BoglerAl MukaddamIoana PiscociuIpsen EuronextAmy WolfMichelle DavisEdward HsiaoRachel ReiffDrug AdministrationMineral ResearchUs Head Of Franchise CommunicationsEuropean CommissionGlobal Head Of Franchise CommunicationsHead Of ResearchAssociation Global RegistryVal HealthDivision Of EndocrinologyInternational Fibrodysplasia Ossificans Progressiva